Gene therapy for malignant glioma

Expert Review of Neurotherapeutics
Maciej S Lesniak

Abstract

Glioblastoma multiforme represents the most common primary malignant tumor of the adult CNS. Unfortunately, the median survival after surgical intervention alone is less than 6 months and the addition of radiotherapy can extend this time to only 9 months. Consequently, efforts aimed at developing new therapies have focused on new treatment strategies that specifically target tumor cells and spare normal cells. One such modality, gene therapy, has shown promise in the spectrum of agents utilized against brain tumors. This review highlights the principles of gene therapy and discusses the results of recent clinical trials in which gene therapy has been employed against malignant brain tumors.

References

May 1, 1992·The Journal of Surgical Research·K W ReichardJ A Greager
May 23, 1991·The New England Journal of Medicine·P M Black
May 30, 1991·The New England Journal of Medicine·P M Black
Feb 1, 1995·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·N Miller, R Vile
Jan 17, 1995·International Journal of Cancer. Journal International Du Cancer·A GuhaC D Stiles
Aug 17, 1994·Journal of the National Cancer Institute·R M LorenceM E Peeples
Aug 1, 1994·The Journal of General Virology·T Valyi-NagyN W Fraser
Mar 25, 1993·Nature·F Mavilio, C Bordignon
Jul 1, 1996·The Annals of Otology, Rhinology, and Laryngology·E A GoebelJ A Kern
Sep 26, 1997·Nature·I M Verma, N Somia
Apr 16, 1998·Nature·C L AndersonB Okamura
Nov 13, 1998·Science·M C CoffeyP W Lee
May 11, 1999·JAMA : the Journal of the American Medical Association·L K Csatary, T Bakács
Feb 19, 2000·Proceedings of the National Academy of Sciences of the United States of America·J N ParkerJ M Markert
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·T W TraskR G Grossman
Feb 24, 2001·Journal of Immunotherapy·B ChenI Fodor
Apr 3, 2001·Annual Review of Neuroscience·R Wechsler-Reya, M P Scott
May 23, 2001·Critical Reviews in Oncology/hematology·E GalanisS J Russell
Jun 8, 2001·Genes & Development·E A MaherR A DePinho
Jun 21, 2001·Journal of the National Cancer Institute·M E WilcoxP A Forsyth
Jun 11, 2003·Recent Progress in Hormone Research·Robert J Wechsler-Reya
Dec 20, 2003·Journal of Neuro-oncology·Amish C ShahJames M Markert
Apr 10, 2004·Journal of Neuro-oncology·L K CsataryC M Csatary
May 12, 2004·Nature Reviews. Drug Discovery·Jeremy N Rich, Darell D Bigner

❮ Previous
Next ❯

Citations

May 24, 2014·Expert Review of Neurotherapeutics·Jacob S YoungMaciej S Lesniak
Sep 13, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Kelsie F TimbieRichard J Price
Oct 30, 2007·Neurologic Clinics·Sith SathornsumeteeDavid A Reardon
Aug 19, 2009·The Journal of Gene Medicine·Suvobroto NandiMaciej S Lesniak
Dec 9, 2014·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Anthony J KimJustin Hanes

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

© 2022 Meta ULC. All rights reserved